Palisade Bio (PALI) Cash from Investing Activities (2010 - 2022)
Palisade Bio (PALI) posted quarterly Cash from Investing Activities of -$10000.0 for Q4 2022, up 97.13% quarter-over-quarter from -$348000.0 in Q3 2021.
Powered by 
Analysis
Palisade Bio (PALI) Cash from Investing Activities (2010 - 2022) Analysis & Trends
Palisade Bio (PALI) has reported Cash from Investing Activities for 12 consecutive years, with -$10000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Cash from Investing Activities changed N/A year-over-year to -$10000.0; the TTM figure through Sep 2024 stood at -$10000.0 (changed 0.0% YoY), while the FY2023 annual figure was -$4000.0, up 60.0% from the prior year.
- Cash from Investing Activities grew to -$10000.0 in Q4 2022 per PALI's latest filing, from -$348000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.0 million in Q1 2018 and bottomed at -$348000.0 in Q3 2021.
- Historically, Cash from Investing Activities has averaged $773381.0 across 4 years, with a median of -$1357.0 in 2018.
- Annual changes were most pronounced in 2018 — Cash from Investing Activities tumbled 320.1% — and 2021, when it slumped 34900.0%.
- Palisade Bio's Cash from Investing Activities stood at -$1714.0 in 2018, then soared by 41.66% to -$1000.0 in 2020, then tumbled by 34700.0% to -$348000.0 in 2021, then surged by 97.13% to -$10000.0 in 2022.
- Business Quant data shows PALI's Cash from Investing Activities at -$10000.0 in Q4 2022, -$348000.0 in Q3 2021, and -$1000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -10,000.00 |
| Sep 30, 2021 | -348,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Dec 31, 2018 | -1,714.00 |
| Mar 31, 2018 | 5.00 Mn |
| Dec 31, 2017 | -408.00 |
| Sep 30, 2017 | -190.00 |
| Dec 31, 2016 | -5.03 Mn |
| Jun 30, 2016 | -100,926.00 |
| Mar 31, 2016 | 7.49 Mn |
| Dec 31, 2015 | -2.55 Mn |
| Sep 30, 2015 | 9.99 Mn |
| Jun 30, 2015 | -92,924.00 |
| Mar 31, 2015 | -98,276.00 |
| Dec 31, 2014 | -76,041.00 |
| Sep 30, 2014 | -95,092.00 |
| Jun 30, 2014 | -169,538.00 |
| Mar 31, 2014 | -15.22 Mn |
| Dec 31, 2013 | -92,329.00 |